Tumor organoid-immune co-culture models bridge the gap between conventional 2D cell lines and in vivo models by preserving key characteristics of the original tumor, including heterogeneity, architecture, and genetic stability. These systems integrate patient-derived or established tumor organoids with various immune cell types such as autologous or allogeneic T cells, natural killer (NK) cells, or macrophages to recapitulate critical aspects of the tumor immune microenvironment. This platform is instrumental for dissecting mechanisms of immune evasion, evaluating the efficacy of immunotherapies, such as immune checkpoint inhibitors, bispecific antibodies, and CAR-T cells, and studying fundamental immunobiology in a controlled yet complex setting.
The experimental design of co-culture models is fundamentally guided by the source of immune cells relative to the tumor tissue, which dictates biological relevance and application scope.
Tumor organoid-immune co-culture models serve as a vital experimental platform in tumor immunology, enabling the study of dynamic tumor-immune interactions. They are critical for dissecting mechanisms of immune evasion and therapy resistance, as well as for developing and validating novel immunotherapeutic strategies in vitro.
Developing Novel Immunotherapy
Serving as a highly predictive preclinical platform for evaluating next-generation immunotherapies, including cell-based therapies (CAR-T, CAR-NK), bispecific antibodies, oncolytic viruses, and novel immune checkpoint modulators, both as monotherapies and in rational combination regimens.
Customized Therapy Screening
Utilizing tumor organoids co-cultured with autologous immune cells to create an ex vivo system. This enables functionally testing an individual response to a panel of approved or investigational immunotherapies, aiming to identify the most effective therapeutic strategy and predict outcomes.
Studying TME Mechanisms
Dissecting the complex, dynamic crosstalk within the tumor immune microenvironment. Applications include elucidating mechanisms of immune evasion, T-cell exhaustion, macrophage polarization, the role of immunosuppressive cytokines and metabolites, and the spatial organization of immune cells within the tumor niche.
Combining deep expertise in 3D tumor biology with specialized immunology capabilities, Alfa Cytology's service delivers robust, standardized, and physiologically relevant co-culture models. This integrated approach ensures clients receive tailored model systems that generate actionable, high-quality data to accelerate immunotherapy research and development pipelines.
Alfa Cytology provides fully customized tumor organoid-immune co-culture model development services. Tailored to specific research objectives, we support diverse immune cell components and various co-culture methodologies. Our end-to-end service ensures precise model design and robust establishment aligned with your experimental goals.
By Cell Types
Integrating key immune effector and antigen-presenting cell populations to accurately reconstruct the complex cellular interactions within the native tumor immune microenvironment.
By Co-culture Method
Selecting from and optimizing a suite of advanced technological platforms, each designed to simulate specific spatial and paracrine interactions, from direct cell contact to sophisticated compartmentalized signaling.
Alfa Cytology's customization extends to developing models that recapitulate the unique biology and immune microenvironment of specific cancer types. We tailor protocols to address distinct research challenges, ensuring biological relevance across a broad spectrum of malignancies.
Alfa Cytology's end-to-end research services support both fundamental discovery and applied preclinical studies. For basic research, we enable the deconstruction of complex tumor-immune interactions and signaling networks. In the preclinical sphere, we facilitate drug candidate evaluation, combination therapy optimization, and the development of patient-specific therapeutic strategies, thereby de-risking translation from bench to bedside.
To establish a robust platform for evaluating adoptive T cell therapy, we developed a cervical cancer organoid-tumor infiltrating lymphocytes (TILs) co-culture model. Autologous TILs were expanded ex vivo and co-cultured with matched organoids under optimized conditions, employing specific labeling and control setups including MHC blockade to confirm antigen-specific interactions. This co-culture system demonstrated significant tumor-specific cytotoxicity, evidenced by a marked increase in apoptotic organoid cells compared to control groups. Concurrently, TILs exhibited enhanced functional activation, characterized by elevated secretion of interferon-gamma (IFN-γ) and increased expression of the activation marker CD137. These results validated the model's ability to recapitulate key immunotherapy response markers, supporting its utility for in vitro efficacy testing and mechanistic studies of T cell-mediated killing in cervical cancer.
Fig.1 Assessment of tumor-specific TIL cytotoxicity in cervical cancer organoid models. (A) Frequency of caspase 3/7+ apoptotic cells, as quantified by flow cytometry. (B) Concentration of IFN-γ in co-culture supernatants, measured by ELISA. (C) Expression of the T cell activation marker CD137 on CD8+ T cells across each group. Data are presented as mean ± SEM (n=5; *p < 0.05, ***p < 0.001).
Offering a critical bridge between traditional models and clinical reality, Alfa Cytology's tumor organoid-immune co-culture services provide insight into immunotherapy mechanisms and efficacy. To discuss how these advanced models can be tailored to advance your specific research or drug development program, please contact our scientific team for a detailed consultation.
Reference
For research use only.
Alfa Cytology is a preclinical research service provider specializing in tumor organoid development. We provide one-stop services that include tailored 3D cancer models, organoid-based research services, and related products to accelerate the discovery and development of cancer therapeutics.
Copyright © 2026 Alfa Cytology. All rights reserved.